Sie suchten nach: emtanzin (Kroatisch - Englisch)

emtanzin se ne
do not administer

emtanzin se ne smije
treatment with

trastuzumab emtanzin n = 495
trastuzumab emtansine n = 495

djelatna tvar je trastuzumab emtanzin.
the active substance is trastuzumab emtansine.

biotransformacija (trastuzumab emtanzin i dm1)
biotransformation (trastuzumab emtansine and dm1)

trastuzumab emtanzin se primjenjuje intravenski.
trastuzumab emtansine is administered intravenously.

emtanzin se odnosi na kompleks mcc-dm1.
emtansine refers to the mcc-dm1 complex.

klinički značaj protutijela na trastuzumab emtanzin još nije poznat.
the clinical significance of anti-trastuzumab emtansine antibodies is not yet known.

mora se provjeriti da je nezaštićeni naziv lijeka trastuzumab emtanzin.
it must be verified that the non-proprietary name is trastuzumab emtansine.

kadcyla 100 mg prašak za koncentrat za otopinu za infuziju trastuzumab emtanzin
kadcyla 100 mg powder for concentrate for solution for infusion trastuzumab emtansine

kao i svi terapijski proteini, trastuzumab emtanzin može izazvati imuni odgovor.
as with all therapeutic proteins, there is the potential for an immune response to trastuzumab emtansine.

trastuzumab emtanzin ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
trastuzumab emtansine has no or negligible influence on the ability to drive and use machines.

kadcyla 100 mg prašak za koncentrat za otopinu za infuziju kadcyla 160 mg prašak za koncentrat za otopinu za infuziju trastuzumab emtanzin
kadcyla100 mg powder for concentrate for solution for infusion kadcyla 160 mg powder for concentrate for solution for infusion trastuzumab emtansine

ako se kadcyla propisuje elektroničkim putem, važno je provjeriti da je propisan lijek trastuzumab emtanzin, a ne trastuzumab.
if a prescription for kadcyla is written electronically, it is important to ensure that the medication prescribed is trastuzumab emtansine and not trastuzumab.

trastuzumab emtanzin nije ispitivan u bolesnika s teškim oštećenjem jetrene funkcije (child-pugh stadij c).
trastuzumab emtansine has not been studied in patients with severe hepatic impairment (child-pugh class c).

inhibicijom polimerizacije tubulina, i dm1 i trastuzumab emtanzin zaustavljaju rast stanica u fazi g2/m staničnog ciklusa, što naposljetku dovodi do apoptotske stanične smrti.
by inhibiting tubulin polymerization, both dm1 and trastuzumab emtansine cause cells to arrest in the g2/m phase of the cell cycle, ultimately leading to apoptotic cell death.

trastuzumab emtanzin se ne smije primjenjivati dok se ukupni bilirubin ne vrati na vrijednost stupnja ≤ 1 (> ggn do 1,5 x ggn).
do not administer trastuzumab emtansine until total bilirubin recovers to grade  1 (>uln to 1.5x uln).

kupina koja je primala trastuzumab emtanzin: 3,6 mg/kg trastuzumab emtanzina intravenski tijekom 30-90 minuta 1. dana 21-dnevnog ciklusa
trastuzumab emtansine arm: trastuzumab emtansine 3.6 mg/kg intravenously over 30-90 minutes on day 1 of a 21-day cycle

trastuzumab emtanzin nije ispitivan u bolesnika koji su prije početka liječenja imali vrijednost serumskih transaminaza > 2,5  ggn ili vrijednost ukupnog bilirubina > 1,5  ggn.
trastuzumab emtansine has not been studied in patients with serum transaminases > 2.5  uln or total bilirubin > 1.5  uln prior to initiation of treatment.

u svrhu sprečavanja medikacijskih pogrešaka, važno je provjeriti naljepnice na bočicama kako biste bili sigurni da je lijek koji se priprema i primjenjuje herceptin (trastuzumab), a ne trastuzumab emtanzin.
in order to prevent medication errors it is also important to check the vial labels to ensure that the medicine being prepared and given is herceptin (trastuzumab) and not trastuzumab emtansine.